Regeneron Follows REGEN-COV Revenue Success With Impressive PD-1 Data

Libtayo Showed Efficacy With Chemo In 1L NSCLC

Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.

Regeneron Pharmaceuticals, Inc. reported stellar second quarter sales and earnings on 5 August with revenues up 163% to $5.14bn, powered by $2.76bn in revenues from REGEN-COV, the antibody cocktail for the treatment of COVID-19. That success should help support the company’s goals in oncology, where it has a wave of new bispecifics in the clinic and new data that will help its late-to-market PD-1 inhibitor Libtayo compete in the challenging lung cancer market.

Excluding REGEN-COV (casirivimab/imdevimab), the company reported solid 22% growth with key brands Eylea (aflibercept), Dupixent (dupilumab) and Libtayo (cemiplimab) delivering...